2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.
Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses the safety profile of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study (NCT04133636).
The main hematologic toxicities observed with cilta-cel on the study were similar to those reported in the phase 1/2 CARTITUDE-1 trial (NCT03548207); they included neutropenia, anemia, and thrombocytopenia, according to Cohen. These toxicities are most often associated with lymphodepletion conditioning therapy, as well as the CAR T-cell therapy itself, Cohen explains.
The rates of grade 3/4 thrombocytopenia and anemia appeared to be less than what was reported on CARTITUDE-1, and prolonged grade 3/4 cytopenias also occurred less frequently; this may be because the CARTITUDE-2 study enrolled a less heavily pretreated population, Cohen concludes.